43.31
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$43.61
Aprire:
$43.73
Volume 24 ore:
2.84M
Relative Volume:
0.21
Capitalizzazione di mercato:
$88.20B
Reddito:
$47.70B
Utile/perdita netta:
$5.07B
Rapporto P/E:
17.47
EPS:
2.4784
Flusso di cassa netto:
$14.58B
1 W Prestazione:
-3.04%
1M Prestazione:
-6.52%
6M Prestazione:
-12.24%
1 anno Prestazione:
-18.83%
Bristol Myers Squibb Co Stock (BMY) Company Profile
Nome
Bristol Myers Squibb Co
Settore
Industria
Telefono
(609) 252-4621
Indirizzo
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Confronta BMY con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
BMY
Bristol Myers Squibb Co
|
43.33 | 89.15B | 47.70B | 5.07B | 14.58B | 2.4784 |
![]()
LLY
Lilly Eli Co
|
830.78 | 728.24B | 53.26B | 13.80B | -50.20M | 15.08 |
![]()
JNJ
Johnson Johnson
|
193.03 | 459.63B | 92.15B | 25.12B | 18.18B | 10.36 |
![]()
ABBV
Abbvie Inc
|
226.78 | 404.77B | 58.33B | 3.73B | 18.24B | 2.1013 |
![]()
NVS
Novartis Ag Adr
|
130.73 | 252.16B | 53.40B | 13.68B | 16.89B | 6.8864 |
![]()
MRK
Merck Co Inc
|
84.63 | 211.56B | 63.43B | 16.42B | 14.72B | 6.4861 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-08-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
2025-04-22 | Iniziato | Piper Sandler | Overweight |
2024-12-16 | Aggiornamento | Jefferies | Hold → Buy |
2024-12-10 | Ripresa | BofA Securities | Neutral |
2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
2024-11-13 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
2024-11-12 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
2024-10-25 | Downgrade | Citigroup | Buy → Neutral |
2024-10-17 | Iniziato | Bernstein | Mkt Perform |
2024-07-29 | Downgrade | Barclays | Overweight → Equal Weight |
2024-03-11 | Downgrade | Societe Generale | Buy → Hold |
2024-02-06 | Downgrade | Redburn Atlantic | Buy → Neutral |
2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
2023-11-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
2023-11-09 | Iniziato | Deutsche Bank | Hold |
2023-11-02 | Downgrade | Daiwa Securities | Outperform → Neutral |
2023-10-27 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
2023-10-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
2023-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
2023-10-20 | Ripresa | UBS | Neutral |
2023-07-14 | Iniziato | HSBC Securities | Reduce |
2023-07-10 | Iniziato | SVB Securities | Market Perform |
2023-06-28 | Iniziato | Daiwa Securities | Outperform |
2023-03-06 | Iniziato | Jefferies | Hold |
2023-01-17 | Iniziato | Cantor Fitzgerald | Overweight |
2022-11-18 | Iniziato | Credit Suisse | Neutral |
2022-10-10 | Downgrade | Guggenheim | Buy → Neutral |
2022-09-14 | Downgrade | Berenberg | Buy → Hold |
2022-06-03 | Downgrade | Raymond James | Outperform → Mkt Perform |
2022-04-06 | Ripresa | Morgan Stanley | Underweight |
2021-12-17 | Iniziato | Goldman | Buy |
2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
2021-11-01 | Downgrade | Argus | Buy → Hold |
2021-07-27 | Ripresa | Truist | Buy |
2021-04-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2021-04-13 | Aggiornamento | Truist | Hold → Buy |
2020-11-16 | Aggiornamento | Societe Generale | Hold → Buy |
2020-11-10 | Ripresa | Bernstein | Mkt Perform |
2020-11-06 | Downgrade | Gabelli & Co | Buy → Hold |
2020-10-19 | Aggiornamento | Guggenheim | Neutral → Buy |
2020-09-29 | Iniziato | Berenberg | Buy |
2020-07-28 | Iniziato | Raymond James | Outperform |
2020-04-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
2020-02-27 | Iniziato | Barclays | Equal Weight |
2020-01-06 | Ripresa | Citigroup | Buy |
2019-12-13 | Aggiornamento | Argus | Hold → Buy |
2019-11-22 | Ripresa | Morgan Stanley | Equal-Weight |
2019-10-17 | Ripresa | BofA/Merrill | Buy |
2019-08-14 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
2019-05-28 | Iniziato | Goldman | Buy |
2019-05-20 | Downgrade | Argus | Buy → Hold |
2019-05-03 | Aggiornamento | Barclays | Equal Weight → Overweight |
2019-05-03 | Ripresa | JP Morgan | Overweight |
2019-01-15 | Aggiornamento | Societe Generale | Sell → Buy |
2018-10-22 | Downgrade | Citigroup | Buy → Neutral |
Mostra tutto
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
What machine learning models say about Bristol Myers Squibb CompanyWatch List & Fast Moving Stock Trade Plans - newser.com
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga
insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro’s ChemML Discovery Platform - BioSpace
insitro, Bristol Myers Squibb extend ALS collaboration with AI focus - Investing.com
insitro, Bristol Myers Squibb extend ALS collaboration with AI focus By Investing.com - Investing.com South Africa
BMY Collaboration Advances ALS Treatment Development - GuruFocus
$20M Added to insitro–Bristol Myers Squibb ALS Collaboration; Novel ALS Target Identified - Stock Titan
Kardigan raises $254M to test cardio drugs from Sanofi, BMS and Ionis - Endpoints News
11 Years of Global Patient Week: Bristol Myers Squibb Brings Joy to Patients with Toy-Making Workshops Across the Region - PR Newswire UK
Bristol Myers Squibb acquires cell therapy biotech Orbital for $1.5bn - European Pharmaceutical Review
What Bristol-Myers Squibb (BMY)'s FDA Fast Track for Alzheimer’s Drug Means for Shareholders - simplywall.st
Bristol Myers' $1.5 Billion RNA Gamble: Could Orbital Therapeutics Rewire Its Future? - Smartkarma
What to Expect From Bristol-Myers Squibb's Next Quarterly Earnings Report - inkl
Analyzing net buyer seller activity in Bristol Myers Squibb Company Equity RightWeekly Investment Recap & Smart Investment Allocation Tips - newser.com
Bristol-Myers Squibb (BMY): Strong Growth Pipeline Supports High-Yield Dividend - Yahoo Finance
Why Top Investors Are Buying Bristol-Myers Squibb Co (BMY) - The Acquirer's Multiple
Pharma companies announce direct-to-consumer sales and price cuts in US - Reuters
Bristol Myers Faces Legacy Headwinds But Banks On Its Pipeline - Finimize
Pancreatic Endocrine Tumor Market Set to Witness Significant Growth During the Forecast Period (2025–2034) Owing to the Expected Launch of Therapies | DelveInsight - GlobeNewswire Inc.
Bispecifics in Oncology Market Statistics Expected to Experience Major Growth by 2040, According to DelveInsight | AstraZeneca, I-MAB Biopharm, BioNTech, Bristol Myers Squibb - Barchart.com
Trend analysis for Bristol Myers Squibb Company this weekJuly 2025 Outlook & Weekly Setup with High ROI Potential - newser.com
SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration - BioSpace
Mark Cuban’s Pharmacy Targets Drug Pricing Reform as AstraZeneca Invests $4.5 Billion in Virginia and Bristol Myers Squibb Acquires Orbital Therapeutics for $1.5 Billion - geneonline.com
Stock Looks Undervalued As Bristol Myers Buys Orbital Therapeutics (NYSE:BMY) - Seeking Alpha
2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types - Business Wire
Bristol Myers (BMY) Triggers Milestone Payment with SystImmune C - GuruFocus
Bristol-Myers Squibb (BMY) Stock Analysis: Navigating a 20% Potential Upside Amidst a Robust Dividend Yield - DirectorsTalk Interviews
SystImmune receives $250 million milestone payment from Bristol Myers Squibb - Investing.com
Covington aids Bristol Myers Squibb on Orbital Therapeutics acquisition - ICLG.com
Notable healthcare headlines for the week: Novo Nordisk, Bristol Myers Squibb and J&J in focus - Seeking Alpha
Bristol-Myers Squibb (BMY): Exploring Valuation After Recent Share Price Declines - simplywall.st
Bristol Myers Squibb: Value Emerges From Distress - Seeking Alpha
Bristol Myers Squibb’s Alzheimer’s Drug, BMS-986446, Granted FDA Fast Track Status - Yahoo Finance
Conning Inc. Has $33.17 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Fourpath Capital Management LLC Trims Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
CAR Ts for autoimmune ramp up: BMS buying Orbital for $1.5B - BioWorld MedTech
BMS expands CAR-T portfolio with $1.5bn Orbital buyout - Pharmaceutical Technology
Bristol Myers to buy Cambridge startup Orbital Therapeutics, building out cell therapy pipeline - The Boston Globe
Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push | Business Information & News | FE - Westlaw Today
What's Going On With Bristol Myers Squibb Stock Friday?Bristol-Myers Squibb (NYSE:BMY) - Benzinga
Bristol Myers Expands Cell Therapy Portfolio With Orbital Therapeutics Acquisition - Sahm
Bristol-Myers Squibb (BMY) Expands Cell Therapy Portfolio with $1.5 Billion Acquisition - GuruFocus
Chart based analysis of Bristol Myers Squibb Company trendsEntry Point & Fast Moving Market Watchlists - newser.com
Bristol Myers Squibb buys Cambridge biotech for $1.5B - The Business Journals
BMS latest to enter in vivo CAR-T field with $1.5B Orbital buy - FirstWord Pharma
Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push - Reuters
Bristol Myers Squibb To Acquire Orbital Therapeutics - citybiz
Bristol Myers makes $1.5B bid for Orbital Therapeutics - The Pharma Letter
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push By Reuters - Investing.com
Bristol Myers (BMY) to Acquire Orbital Therapeutics in $1.5 Bill - GuruFocus
Bristol Myers Squibb Co Azioni (BMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):